Ishita Drugs & Industries Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 444125, "name": "Ishita Drugs", "stock_name": "Ishita Drugs", "full_name": "Ishita Drugs & Industries Ltd", "name_url": "stocks-analysis/ishita-drugs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "81.50", "chg": 3.8, "chgp": "4.89%", "dir": 1, "prev_price": "77.70", "mcapval": "24.00 Cr", "mcap": "Micro Cap", "scripcode": 524400, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE806D01016", "curr_date": "Jun 05, 03:30 PM", "curr_time": "19:23 PM", "last_traded_at": "Jun 05, 03:30 PM IST", "bse_nse_vol": "74 ", "exc_status": "Active", "traded_date": "Jun 05, 2026", "traded_date_str": "2026 06 05", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Ishita Drugs & Industries Ltd: Valuation Shift Signals Price Attractiveness Change", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shift-signals-price-attractiveness-change-4032684", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_valuationdot_4032684.png", "date": "2026-06-03 08:00:26", "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a change in price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector. This article analyses the implications of these valuation changes, comparing key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios against industry benchmarks and historical trends, providing investors with a comprehensive view of the stock’s current standing." }, { "title": "Are Ishita Drugs & Industries Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-industries-ltd-latest-results-good-or-bad-4024797", "imagepath": "", "date": "2026-05-31 19:20:43", "description": "Ishita Drugs & Industries Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹3.06 crores, reflecting a sequential decline of 2.55% from the previous quarter and a substantial year-on-year decrease of 32.89%. This pattern of revenue contraction indicates a troubling trend, particularly given the erratic sales performance over recent quarters, which has seen fluctuations ranging from a high of ₹5.40 crores to the current low.\n\nOn the profit side, the net profit for the quarter was ₹0.18 crores, which represents a 12.50% increase compared to the previous quarter, although it is down 37.93% year-on-year. This improvement in net profit is largely attributed to a significant increase in other income, which raises questions about the sustainability of earnings derived from core operations.\n\nOperating margins have also come under pressure, declin..." }, { "title": "Ishita Drugs Q4 FY26: Revenue Decline and Margin Pressure Test Micro-Cap Pharma Player", "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q4-fy26-revenue-decline-and-margin-pressure-test-micro-cap-pharma-player-4024534", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IshitaDrugsIndu_quaterlyResult_4024534.png", "date": "2026-05-30 23:48:50", "description": "Ishita Drugs & Industries Ltd., an Ahmedabad-based active pharmaceutical ingredient (API) manufacturer, reported challenging Q4 FY26 results marked by significant revenue contraction and margin compression. The company posted a net profit of ₹0.18 crores for the quarter ended March 2026, representing a 12.50% increase quarter-on-quarter but a concerning 37.93% decline year-on-year. With a modest market capitalisation of ₹24.00 crores, the micro-cap pharma player faces mounting operational headwinds as it navigates a difficult industry environment." }, { "title": "Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4004181", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IshitaDrugsIndu_valuationdot_4004181.png", "date": "2026-05-22 08:00:21", "description": "Ishita Drugs & Industries Ltd has witnessed a notable improvement in its valuation parameters, shifting from a fair to an attractive rating. This change comes amid a complex market backdrop where the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have adjusted favourably relative to historical averages and peer benchmarks, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector." }, { "title": "Ishita Drugs & Industries Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-is-rated-sell-4002791", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IshitaDrugsIndu_mojoScore_4002791.png", "date": "2026-05-21 10:10:22", "description": "Ishita Drugs & Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-3965337", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IshitaDrugsIndu_valuationdot_3965337.png", "date": "2026-04-28 08:00:37", "description": "Ishita Drugs & Industries Ltd has witnessed a notable improvement in its valuation parameters, shifting from a fair to an attractive rating despite a recent 4.6% decline in its share price. This micro-cap pharmaceutical player’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more compelling entry point relative to its historical averages and peer group, signalling a potential opportunity for discerning investors amid a challenging sector backdrop." }, { "title": "Ishita Drugs Gains 6.11%: 2 Key Factors Driving the Weekly Move", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-gains-611-2-key-factors-driving-the-weekly-move-3962798", "imagepath": "", "date": "2026-04-25 17:08:19", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>20 Apr:</strong> Stock opens at Rs.77.00, modest gain despite flat Sensex</p>\n <p><strong>21 Apr:</strong> Upgrade to Sell rating announced; stock surges 4.35% to Rs.80.35</p>\n <p><strong>22 Apr:</strong> Valuation shift to fair grade; stock dips 3.78% to Rs.77.31</p>\n <p><strong>23 Apr:</strong> Recovery rally lifts stock 4.64% to Rs.80.90 despite Sensex decline</p>\n <p><strong>24 Apr:</strong> Slight pullback to Rs.80.71; week closes with 6.11% gain</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div cl..." }, { "title": "Ishita Drugs & Industries Ltd Upgraded to Sell on Technical and Valuation Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-upgraded-to-sell-on-technical-and-valuation-improvements-3957211", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IshitaDrugsIndu_mojoScore_3957211.png", "date": "2026-04-22 08:11:01", "description": "Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 April 2026, reflecting a nuanced improvement in technical indicators and valuation metrics despite persistent challenges in financial trends and quality parameters. The micro-cap pharmaceutical company’s Mojo Score has risen to 31.0, signalling a cautious but positive shift in market sentiment." }, { "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-changing-price-attractiveness-3956588", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IshitaDrugsIndu_valuationdot_3956588.png", "date": "2026-04-22 08:00:42", "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating as of 21 April 2026. This change reflects evolving market perceptions amid a competitive Pharmaceuticals & Biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now aligning more closely with peer averages. Despite a recent 4.38% intraday price rise, the company’s overall mojo grade has been downgraded from Strong Sell to Sell, signalling caution for investors." } ], "total": 120, "sid": "444125", "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125" }, "announcements": [ { "caption": "Outcome Of Board Meeting Held On 30Th May 2026", "datetime": "30-May-2026", "details": "Audited Financial Results for the quarter and year ended 31st March 2026", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th May 2026", "datetime": "30-May-2026", "details": "Outcome of Board Meeting held on 30th May 2026", "source": "BSE" }, { "caption": "Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter And Year Ended 31St March 2026", "datetime": "23-May-2026", "details": "Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve 1. To consider approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 33rd Annual General Meeting of the Company. 3. To consider the re-appointment of Internal Auditors of the Company for the year 2026-27. 4. To take on record Disclosure of Interest of Directors. 5. Any other matter with permission of the Chair.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

20 Apr: Stock opens at Rs.77.00, modest gain despite flat Sensex

21 Apr: Upgrade to Sell rating announced; stock surges 4.35% to Rs.80.35

22 Apr: Valuation shift to fair grade; stock dips 3.78% to Rs.77.31

23 Apr: Recovery rally lifts stock 4.64% to Rs.80.90 despite Sensex decline

24 Apr: Slight pullback to Rs.80.71; week closes with 6.11% gain

Week Open

Read full news article

Ishita Drugs & Industries Ltd Upgraded to Sell on Technical and Valuation Improvements

2026-04-22 08:11:01

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 April 2026, reflecting a nuanced improvement in technical indicators and valuation metrics despite persistent challenges in financial trends and quality parameters. The micro-cap pharmaceutical company’s Mojo Score has risen to 31.0, signalling a cautious but positive shift in market sentiment.

Read full news article

Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness

2026-04-22 08:00:42

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating as of 21 April 2026. This change reflects evolving market perceptions amid a competitive Pharmaceuticals & Biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now aligning more closely with peer averages. Despite a recent 4.38% intraday price rise, the company’s overall mojo grade has been downgraded from Strong Sell to Sell, signalling caution for investors.

Read full news article